Henry Schein (NASDAQ:HSIC) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Henry Schein (NASDAQ:HSIC) from a buy rating to a hold rating in a research report released on Sunday.

Several other analysts also recently issued reports on the company. Barclays reissued an “overweight” rating and issued a $100.00 price target (up from $86.00) on shares of Henry Schein in a research note on Thursday. BTIG Research reiterated a “buy” rating and set a $100.00 price objective on shares of Henry Schein in a report on Wednesday, August 5th. Morgan Stanley restated an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Barrington Research set a $104.00 price target on Henry Schein in a research report on Wednesday. Finally, Robert W. Baird set a $97.00 price target on shares of Henry Schein in a research note on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $92.27.

Henry Schein Stock Performance

Shares of HSIC opened at $88.13 on Friday. The firm has a market cap of $9.82 billion, a P/E ratio of 25.69, a PEG ratio of 1.68 and a beta of 0.80. Henry Schein has a twelve month low of $61.94 and a twelve month high of $92.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. The firm’s 50 day moving average price is $83.49 and its two-hundred day moving average price is $78.66.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.03. The company had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, analysts forecast that Henry Schein will post 5.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein in the second quarter valued at $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein during the 2nd quarter worth about $27,000. Flagship Harbor Advisors LLC acquired a new position in shares of Henry Schein during the 4th quarter worth about $30,000. Federated Hermes Inc. bought a new stake in shares of Henry Schein in the 4th quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Henry Schein in the 4th quarter valued at about $37,000. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.